PBLA | Panbela Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.3150 - 0.3151
52 Week Range	0.3000 - 22.80
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	4
Average Volume	9,466
Shares Outstanding	4,854,830
Market Cap	1,529,271
Sector	Healthcare
Industry	Biotechnology
IPO Date	2017-01-03

Valuation
Profitability
Growth
Health
P/E Ratio	-0.01
Forward P/E Ratio	N/A
EPS	-34.51
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	7
Country	USA
Website	PBLA

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

PBLA's peers: ADTX, ATXI, DARE, DRMA, GTBP, ITRM, KPRX, MBRX, PSTV, SNGX, TENX, UBX, VRPX, VTGN, TOVX

*Chart delayed

Analyzing fundamentals for PBLA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see PBLA Fundamentals page.

Watching at PBLA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on PBLA Technicals page.